Akèy › Kasinòm epitelyal ovè › Tennessee
Etid klinik pou Kasinòm epitelyal ovè nan Tennessee
6 etid pou Kasinòm epitelyal ovè ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Erlanger Health, Chattanooga
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Sep 15, 2026 · NCT06915025Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer
- University of Tennessee Medical Center - Knoxville, Knoxville
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Fanm · Mizajou Aug 17, 2026 · NCT07764133AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Germantown
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Sarah Cannon Research Institute (Oncology Associates of Oregon PC), Nashville
Ap rekriteFaz 3
Laj 18 ak plis · Fanm · Mizajou Jul 2, 2026 · NCT06819007CT-95 in Advanced Cancers Associated With Mesothelin Expression
- Context Investigational Site, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT06756035Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 15, 2025 · NCT04429542Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.